Literature DB >> 10683302

Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse.

J Van Beek1, M Bernaudin, E Petit, P Gasque, A Nouvelot, E T MacKenzie, M Fontaine.   

Abstract

In the present study, we have examined the expression of anaphylatoxin C3a and C5a receptors (C3aR and C5aR) at the mRNA and protein levels in ischemic brain tissues following permanent middle cerebral artery (MCA) occlusion in the mouse. C3aR and C5aR mRNAs were both detected by semiquantitative reverse transcription and polymerase chain reaction (RT-PCR) and the cellular distribution of each receptor was analyzed by immunohistochemistry. Significant increases in the expression of C3aR and C5aR mRNAs in the ischemic cortex were observed; the expression of both reached a peak at 2 days after MCA occlusion (4.3- and 3.4-fold increases, respectively, compared with nonoperated control cortical samples; P < 0.00625 with Bonferroni's correction, n = 3). C3aR and C5aR stainings were found constitutively on neurons and astrocytes. In ischemic tissues, we observed that C3aR and C5aR were expressed de novo on endothelial cells of blood vessels, at 6 h and 2 days after MCA occlusion, respectively. C3aR and C5aR immunostaining was increased in macrophage-like cells and reactive astrocytes 7 days postocclusion. C3a and C5a may play an important role in promoting inflammatory and/or repair processes in the ischemic brain by regulating glial cell activation and chemotaxis. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683302     DOI: 10.1006/exnr.1999.7273

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  48 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 2.  The Role of Complement C3a Receptor in Stroke.

Authors:  Saif Ahmad; Kanchan Bhatia; Adam Kindelin; Andrew F Ducruet
Journal:  Neuromolecular Med       Date:  2019-05-17       Impact factor: 3.843

Review 3.  Complement inhibition as a proposed neuroprotective strategy following cardiac arrest.

Authors:  Brad E Zacharia; Zachary L Hickman; Bartosz T Grobelny; Peter A DeRosa; Andrew F Ducruet; E Sander Connolly
Journal:  Mediators Inflamm       Date:  2010-01-26       Impact factor: 4.711

4.  Complement Peptide C3a Promotes Astrocyte Survival in Response to Ischemic Stress.

Authors:  Noriko Shinjyo; Yolanda de Pablo; Milos Pekny; Marcela Pekna
Journal:  Mol Neurobiol       Date:  2015-05-14       Impact factor: 5.590

5.  Expression of C5a and its receptor following spinal cord ischemia reperfusion injury in the rat.

Authors:  Q Dong; L Sun; L Peng; B Yan; J Lv; G Wang; S Gong
Journal:  Spinal Cord       Date:  2015-04-28       Impact factor: 2.772

6.  Evaluation of capsular and acapsular strains of S. aureus in an experimental brain abscess model.

Authors:  Nilufer Esen; Gail Wagoner; Napoleon Philips
Journal:  J Neuroimmunol       Date:  2009-11-10       Impact factor: 3.478

7.  C3aR inhibition reduces neurodegeneration in experimental lupus.

Authors:  A Jacob; L Bao; J Brorson; R J Quigg; J J Alexander
Journal:  Lupus       Date:  2009-11-09       Impact factor: 2.911

Review 8.  Phytochemicals in Ischemic Stroke.

Authors:  Joonki Kim; David Yang-Wei Fann; Raymond Chee Seong Seet; Dong-Gyu Jo; Mark P Mattson; Thiruma V Arumugam
Journal:  Neuromolecular Med       Date:  2016-05-18       Impact factor: 3.843

9.  Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury.

Authors:  Ying Wang; Yansong Li; Shawn L Dalle Lucca; Milomir Simovic; George C Tsokos; Jurandir J Dalle Lucca
Journal:  J Neuroinflammation       Date:  2010-04-09       Impact factor: 8.322

10.  The role of the complement system and the activation fragment C5a in the central nervous system.

Authors:  Trent M Woodruff; Rahasson R Ager; Andrea J Tenner; Peter G Noakes; Stephen M Taylor
Journal:  Neuromolecular Med       Date:  2009-09-11       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.